文献速递间质性肺疾病

自身免疫性肺泡蛋白沉积症

Autoimmune Pulmonary Alveolar Proteinosis.
PubMed 文献 · Am J Respir Crit Care Med · 2022-01-01

自身免疫性肺泡蛋白沉积症是一种罕见病,由髓系细胞功能障碍、异常肺表面活性物质积累和先天免疫缺陷引起,患病率为7-10/百万,占所有PAP综合征患者的90%。最常见的表现是隐匿起病的呼吸困难伴或不伴咳嗽、少量白色泡沫痰和弥漫性影像学浸润,常见于既往健康的成人,但也可发生于3岁儿童。低患病率和非特异性临床、影像和实验室发现常导致误诊为肺炎并显著延迟准确诊断,临床病程虽可变但通常包括进行性低氧性呼吸功能不全。

要点

  • 自身免疫性PAP患病率7-10/百万,占PAP综合征90%,由GM-CSF自身抗体驱动。
  • 最常见表现为隐匿起病呼吸困难、少量白色泡沫痰和弥漫性影像学浸润。
  • GM-CSF自身抗体血液检测敏感性和特异性均为100%。

核心结论

  • 自身免疫性PAP由GM-CSF自身抗体驱动,基于该机制的诊断血液检测敏感性和特异性均为100%。

研究设计与样本

  • 综述性文章,总结了自身免疫性PAP的流行病学、临床表现、诊断和治疗进展。

主要发现

  • 自身免疫性PAP患病率为7-10/百万,占所有PAP综合征患者的90%。
  • 最常见表现为隐匿起病的呼吸困难伴或不伴咳嗽、少量白色泡沫痰和弥漫性影像学浸润,常见于既往健康成人但也可发生于3岁儿童。
  • 杵状指、发热和咯血不典型,后两者提示可能合并感染。
  • 低患病率和非特异性表现常导致误诊为肺炎并显著延迟诊断。
  • 临床病程通常包括进行性低氧性呼吸功能不全,部分患者出现继发感染、肺纤维化、呼吸衰竭和死亡。

关键数值与推荐

  • GM-CSF自身抗体在血液和组织中高浓度存在,形成准确且商业可用的诊断血液检测基础,敏感性和特异性均为100%。

临床怎么用

  • 全肺灌洗仍是首选治疗,吸入GM-CSF在良好对照试验中显示安全、耐受良好且有效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autoimmune pulmonary alveolar proteinosis (PAP) is a rare disease characterized by myeloid cell dysfunction, abnormal pulmonary surfactant accumulation, and innate immune deficiency. It has a prevalence of 7-10 per million; occurs in individuals of all races, geographic regions, sex, and socioeconomic status; and accounts for 90% of all patients with PAP syndrome. The most common presentation is dyspnea of insidious onset with or without cough, production of scant white and frothy sputum, and diffuse radiographic infiltrates in a previously healthy adult, but it can also occur in children as young as 3 years. Digital clubbing, fever, and hemoptysis are not typical, and the latter two indicate that intercurrent infection may be present. Low prevalence and nonspecific clinical, radiological, and laboratory findings commonly lead to misdiagnosis as pneumonia and substantially delay an accurate diagnosis. The clinical course, although variable, usually includes progressive hypoxemic respiratory insufficiency and, in some patients, secondary infections, pulmonary fibrosis, respiratory failure, and death. Two decades of research have raised autoimmune PAP from obscurity to a paradigm of molecular pathogenesis-based diagnostic and therapeutic development. Pathogenesis is driven by GM-CSF (granulocyte/macrophage colony-stimulating factor) autoantibodies, which are present at high concentrations in blood and tissues and form the basis of an accurate, commercially available diagnostic blood test with sensitivity and specificity of 100%. Although whole-lung lavage remains the first-line therapy, inhaled GM-CSF is a promising pharmacotherapeutic approach demonstrated in well-controlled trials to be safe, well tolerated, and efficacious. Research has established GM-CSF as a pulmonary regulatory molecule critical to surfactant homeostasis, alveolar stability, lung function, and host defense.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. McCarthy C, Carey BC, Trapnell BC, et al. Autoimmune Pulmonary Alveolar Proteinosis. Am J Respir Crit Care Med. 2022. PMID: 35227171. doi:10.1164/rccm.202112-2742SO

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。